Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 22,367 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Clear all
Completed Phase 4 Interventional Results available

Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

NCT01007448
View directory record Official record
Conditions
Refractory Cutaneous T-cell Lymphoma
Interventions
Bexarotene
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
17
States / cities
Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 26, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

NCT04975555
View directory record Official record
Conditions
Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia
Interventions
Siltuximab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 26, 2026, 2:16 PM EDT
Completed Phase 3 Interventional Results available

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

NCT01102426
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Plitidepsin, Dexamethasone
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
5
States / cities
Tuscaloosa, Alabama • Los Angeles, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 26, 2026, 2:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

NCT01484626
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bendamustine
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 26, 2026, 2:16 PM EDT
Recruiting No phase listed Observational

Sample Collection and Tracking for the Developmental Therapeutics Clinic

NCT03269578
View directory record Official record
Conditions
Neoplasms, Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 2:16 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Naltrexone and Hypoglycemia in Type 1 Diabetes

NCT01053078
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia Unawareness
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 26, 2026, 2:16 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
mezigdomide, Pomalidomide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
56
States / cities
Los Alamitos, California • San Diego, California • West Hollywood, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 26, 2026, 2:16 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis

NCT00119015
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Placebo, Montelukast, Fluticasone propionate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 26, 2026, 2:16 PM EDT
Withdrawn Not applicable Interventional

The Utilization of Yoga as a Therapeutic Tool to Promote Physical Activity Behavior Change and Improved Postural Control in Individuals With Multiple Sclerosis

NCT04113135
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Yoga, Control
Other
Lead sponsor
Winston Salem State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 26, 2026, 2:16 PM EDT
Completed No phase listed Observational Results available

Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions

NCT04276935
View directory record Official record
Conditions
High Grade Anal Canal Squamous Intraepithelial Neoplasia, Human Immunodeficiency Virus
Interventions
Interview, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 26, 2026, 2:16 PM EDT
Completed Phase 1 Interventional

A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients

NCT03463135
View directory record Official record
Conditions
Food Allergy
Interventions
Glucopyranosyl Lipid A (GLA), Sublingual Immuno Therapy (SLIT) Peanut Extract (PE), Placebo for GLA, Placebo for SLIT PE
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Little Rock, Arkansas • Mission Viejo, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 26, 2026, 2:16 PM EDT
Completed No phase listed Observational

CTC Immune Checkpoint

NCT02456571
View directory record Official record
Conditions
Prostate Cancer
Interventions
CTC biomarker expression prevalence
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 26, 2026, 2:16 PM EDT
Completed Phase 1Phase 2 Interventional

A Pilot Trial of Rituxan in Refractory Myasthenia Gravis

NCT00619671
View directory record Official record
Conditions
Refractory Myasthenia Gravis
Interventions
Rituximab (Rituxan)
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Syracuse, New York • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 26, 2026, 2:16 PM EDT
Completed Phase 4 Interventional Results available

Anti-HIV Medications for People Recently Infected With HIV

NCT00106171
View directory record Official record
Conditions
HIV Infections
Interventions
Highly active antiretroviral therapy (HAART)
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 26, 2026, 2:16 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer

NCT04913064
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Questionnaire Administration, White Button Mushroom Extract
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 26, 2026, 2:16 PM EDT
Completed Not applicable Interventional Results available

Rapid HIV Treatment Initiation, Access and Engagement in Care

NCT03512964
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Dolutegravir 50 MG, Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet [DESCOVY]
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 26, 2026, 2:16 PM EDT
Completed Not applicable Interventional

A Randomized Trial to Improve Quality of Life Outcomes in Asthma Patients

NCT00197964
View directory record Official record
Conditions
Asthma
Interventions
Enhance asthma knowledge, self-efficacy, social support
Behavioral
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Oct 26, 2026, 2:16 PM EDT
Recruiting Phase 2 Interventional

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

NCT05281809
View directory record Official record
Conditions
B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Chronic Lymphocytic Leukemia, Transformed Lymphoma
Interventions
Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
Drug
Lead sponsor
John Lister
Other
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 26, 2026, 2:16 PM EDT
Completed No phase listed Observational

Wireless Motion Sensors for Rheumatoid Arthritis Patients - Pilot Study

NCT02296632
View directory record Official record
Conditions
Arthritis, Rheumatoid, Medication Adherence
Interventions
Motion sensors and daily online assessments
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 26, 2026, 2:16 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

NCT07137598
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Avondale, Arizona • Peoria, Arizona • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 2:16 PM EDT
Not yet recruiting Not applicable Interventional

VR-PAT and fNIRS to Identify CNS Biomarkers of Pain

NCT06303687
View directory record Official record
Conditions
Acute Pain, Pediatric ALL, Procedural Pain, Burns
Interventions
VR-PAT
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 26, 2026, 2:16 PM EDT
Completed No phase listed Observational

Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

NCT00674193
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET), Unspecified Childhood Solid Tumor, Protocol Specific, Wilms Tumor and Other Childhood Kidney Tumors
Interventions
pharmacological study, laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 16 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 26, 2026, 2:16 PM EDT
Recruiting Phase 2 Interventional

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

NCT05530421
View directory record Official record
Conditions
Relapsed and Refractory Multiple Myeloma
Interventions
Selinexor, Venetoclax, Dexamethasone
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
3
States / cities
Coral Gables, Florida • Deerfield Beach, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 26, 2026, 2:16 PM EDT
Completed Phase 1 Interventional

A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS

NCT00002116
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Cidofovir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 2:16 PM EDT